

Impacting Patient Outcomes with Trusted Cancer Diagnostics

Issar Yazbin

Company name Ibex Medical Analytics

* Website www.ibex-ai.com*

CEO name Joseph Mossel* (Issar Yazbin)*

CATEGORY: Health IT/Digital *

SESSIONS • Digital Biomarkers & Digital Pathology: new tools to enhance therapy

- o Executive Summary / Investment Rational Ibex develops AI-driven applications making pathologists more accurate and efficient in diagnosing cancer. Millions of biopsies are diagnosed annually, many of which mistakenly, resulting in treating patients incorrectly, or not at all, which costs the healthcare system billions of dollars. Ibex collaborates with many industry partners, including Roche, Philips and AstraZeneca. Our solutions are used in dozens of labs globally.

- o Core Technology Ibex feeds input from expert pathologists into machine learning and deep learning algorithms to generate models that can identify dozens of normal and abnormal morphologies in histology micrographs. The unparalleled accuracy of these models has been demonstrated in many studies and published in peer-reviewed publications. By applying these models to digital pathology, pathologists are work faster and make fewer mistakes.

- o Product Profile/Pipeline Ibex offers applications assisting in prostate, breast and gastric biopsy primary diagnosis, as well as in breast HER2 biomarker assessment. We're developing additional tools for breast cancer and for other cancer types, e.g. colorectal. Our applications are sold and used across five continents since 2018. We've partnered with several industry and pharma partners to increase the reach of our offering.

- o Business Strategy Our highly accurate algorithmic models enable our customers – hospital pathology departments, academic medical centers and independent diagnostic labs – to gain unprecedented levels of efficiency and successfully diagnose more patient in less time, thus increasing their income. We're collaborating with industry partners to make our solutions more interoperable and with pharma partners to develop better diagnostic tools for precise therapy selection.

- o What's Next? Ibex consists of 100 employees and is growing. We intend to greatly increase our sales through direct and indirect channels. We continue to develop new algorithms and applications, conduct studies with our academic partners and introduce

new capabilities into our applications to maintain a leading position. Our applications are CE marked our first FDA clearance is expected later this year